Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.87 USD | -10.00% | -23.21% | +3.48% |
Financials (USD)
Sales 2024 * | 4.73M | Sales 2025 * | 4.85M | Capitalization | 440M |
---|---|---|---|---|---|
Net income 2024 * | -195M | Net income 2025 * | -211M | EV / Sales 2024 * | 50.5 x |
Net cash position 2024 * | 202M | Net cash position 2025 * | 124M | EV / Sales 2025 * | 65.2 x |
P/E ratio 2024 * |
-2.08
x | P/E ratio 2025 * |
-2.28
x | Employees | 181 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.53% |
Latest transcript on Fate Therapeutics, Inc.
1 day | -10.00% | ||
1 week | -23.21% | ||
Current month | -47.28% | ||
1 month | -43.67% | ||
3 months | -15.13% | ||
6 months | +115.00% | ||
Current year | +3.48% |
Managers | Title | Age | Since |
---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
Chairman | 75 | 11-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.95% | 1 M€ | 0.00% | - | |
2.10% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 3.87 | -10.00% | 3,601,787 |
24-04-24 | 4.3 | -5.29% | 2,273,158 |
24-04-23 | 4.54 | -5.02% | 4,022,308 |
24-04-22 | 4.78 | -0.21% | 1,434,149 |
24-04-19 | 4.79 | -4.96% | 2,691,663 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.48% | 440M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.93% | 22.02B | |
-17.84% | 20.9B | |
-9.58% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- FATE Stock